Strategic Rebranding Reflects Focus on Neurodegenerative Therapies and Healthy Longevity New York, NY, September 17, 2024 – PRISM MediaWire – The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has launched a new website, www.klothoneuro.com.
Company will use novel, patented Klotho Gene (s-KL) in studies New York, NY, September 4, 2024 – PRISM MediaWire – ANEW MEDICAL, INC. (NASDAQ: WENA), a U.S. biotechnology company, announced that it has two distinct goals for its pioneering cell and gene therapy development.
Successful Conversion Eliminates Over $4 Million in Long-Term Debt New York, NY, August 26, 2024 – ANEW MEDICAL, INC. (NASDAQ: WENA), a leading U.S. biotechnology company pioneering cell and gene-based treatments for aging and age-related diseases, announces the successful conversion of its convertible promissory notes by investors.
| XBER Exchange | US Country |
The described company is centered around an investment strategy that identifies and capitalizes on companies poised for significant growth due to "Transformational Changes" in society. These changes include new trends in remote work, health care, consumer habits, and digital connectivity - trends that have been notably accelerated by the impact of the COVID-19 pandemic. Utilizing a "replication strategy," the firm seeks to match the performance of its index by investing in the component securities in proportions that mirror those of the index itself. This approach aims to benefit from the shift in global dynamics and the advancement of technologies and services that support these evolving consumer and professional behaviors.
This core product of the company targets investment opportunities created by significant societal shifts. By focusing on companies at the forefront of changing how people work, manage health, consume products, and connect digitally, this strategy aims to capitalize on the long-term growth potential accelerated by global events such as the COVID-19 pandemic.
As part of its investment approach, the firm employs a replication strategy to achieve its investment objectives. This entails investing in the securities comprising its target index in proportions that closely approximate the index. This method is designed to replicate the performance of the index, providing investors with a diversified exposure to companies benefiting from transformational societal changes.